$MAZE

Wall Street analysts issued updates on multiple companies. Upgrades include Boyd Gaming (BYD) to Overweight, CoreWeave (CRWV) to Buy, Datadog (DDOG) to Outperform, and Intel (INTC) to Neutral. Downgrades include Ameriprise Financial (AMP) to Underperform, LCI Industries (LCII) to Hold, and PayPal (PYPL) to Underperform. New initiations include Azul (AZUL) with Neutral, Pinterest (PINS) with Buy, and others.

Analysts made several calls: Goldman upgraded CoreWeave to Buy with a $106 target, Morgan Stanley named Amazon a top pick with a $350 target, and raised Meta's target to $820. Bernstein upgraded Datadog, JPMorgan upgraded Intel to Neutral, and Bank of America reiterated Apple as Buy. Other notable upgrades include Boyd Gaming, Dow, Exxon, Global-E Online, Nvidia, Global Payments, Eli Lilly, and Match.

Canaccord Genuity initiated coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and $75.00 price target, citing its kidney disease treatment and pipeline. The stock has a $1.53B market cap and is down 33.55% YTD. Analysts highlight MZE829, an APOL1 inhibitor for kidney disease, and MZE782 for phenylketonuria and chronic kidney disease. Maze holds more cash than debt. Raymond James maintains a Strong Buy rating on MAZE and Market Perform on Vertex Pharmaceuticals (VRTX).

Maze Therapeutics exchanged 2.78M shares for pre-funded warrants with Frazier Life Sciences, exercisable at $0.001. Post-exchange, 53.93M shares are outstanding. The deal, under Section 3(a)(9) of the Securities Act, aims to manage ownership limits and flexibility.

Maze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The information contained below under Item 3.02 is hereby incorporated by reference in response to this Item 1.01 of Form 8-K. Item 3.02. Unregistered Sales of Equity Securities. On October 15 , 2026, Maze Therapeutics, Inc. (

Raymond James maintained its Strong Buy rating on Maze Therapeutics (MAZE) and Market Perform rating on Vertex Pharmaceuticals (VRTX) after survey data indicated strong demand for APOL1-mediated FSGS therapies. Both companies are developing treatments for this condition, with VRTX's inaxaplin ranking as the most desired for approval. MAZE plans to report Phase 2 study results in late 2026 or early 2027, while VRTX expects to present interim analysis data in early 2027.

Maze Therapeutics CEO Jason V. Coloma sold 34,501 shares of the company's stock through two trusts, totaling approximately $932,000. The sales were made under a pre-arranged Rule 10b5-1 trading plan at weighted average prices of $27.0241 and $27.0210 per share, respectively. The transactions occurred on October 1, 2026, with the trusts retaining significant holdings afterward.

Coloma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $27.02 ($27.02–$27.02, $0.93M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Truist analyst Danielle Brill highlighted a positive readthrough for Maze Therapeutics (MAZE) after Vertex Pharmaceuticals (VRTX) reported successful Phase 2 data for a kidney disease treatment. The data supports a large market opportunity, with Truist maintaining a Buy rating and $64 target for Maze. Vertex reported $3.33 billion in Q2 2026 revenue and raised its full-year 2026 guidance to $13.1–$13.2 billion.

Maze Therapeutics (MAZE) stock rose 2.9% in pre-market trading after CIBC initiated coverage with an Outperformer rating and a $50 price target. The company has 13 buy-equivalent ratings. Vertex Pharmaceuticals' (VRTX) positive kidney disease data also boosted MAZE, as both companies work on APOL1 inhibitors. The S&P 500, Dow, and Nasdaq showed little movement, indicating the rally was driven by company-specific news.